G
Genetic Archaeology
GENETIC ARCHAEOLOGY // PROFILE

MSH2

MutS Homolog 2

CHR 2
2p21-p16.3

Overview

The MSH2 gene serves as the frontline DNA proofreading scout inside dividing cells. Partnering with MSH6 (MutSα) or MSH3 (MutSβ), MSH2 slides along freshly copied DNA helices immediately spotting mismatched nucleotides before recruiting MLH1 and PMS2 to splice out the error.

Along with MLH1, pathogenic germline defects in MSH2 account for the vast majority of Lynch syndrome families—where proactive endoscopy prevents polyps from turning malignant, detailed in our hereditary colon cancer guide.

📍 Position
2p21-p16.3 (Chromosome 2)
🏷️ Category
Tumor Suppressor & DNA Repair
🧪 Function
DNA Mismatch Sensor (MMR)
📊 Influence
Lynch syndrome & surveillance

Function of MSH2

Loss of functional MSH2 in a colonic crypt or endometrial lining following a second somatic hit cripples mismatch repair, producing hypermutated microsatellite-instability (MSI-H) tumors—which today actually respond exceptionally well to modern immune checkpoint therapies.

Key Aspects:

🩺 Proactive Colonoscopic Protection

Starting colonoscopies every 1–2 years in early adulthood (age ~20–25) removes adenomas years before invasive carcinoma develops.

🔬 Upstream EPCAM Deletions

In clinical genetics, deletions in the neighboring EPCAM gene can epigenetically silence MSH2, requiring dedicated CNV/MLPA clinical panels beyond basic chips.

💡 Note on Array Chips vs. Clinical Testing: Common tag SNPs like rs2303428 and rs4987188 seen in raw-DNA downloads are not high-penetrance Lynch mutations; full clinical NGS + deletion analysis is essential whenever family red flags appear.

🧬 Genetic Variants (SNPs)

While hundreds of rare private variants trigger clinical Lynch syndrome, two common population polymorphisms help separate benign background variants:

rs2303428
2:47414421
Reference

T
/
Variant

C
MSH2 Intron 12 (T>C)
Common benign-to-low-effect population polymorphism frequently cited in research studies; does not confer high-penetrance Lynch syndrome.
C allele frequency:
~9% (Europe)
rs4987188
2:47416342
Gly322

G
/
Asp322

A
MSH2 Gly322Asp
Mild coding polymorphism classified clinically by InSiGHT/ClinVar as likely benign compared with true truncating MSH2 variants.
A allele frequency:
~1-2% (Europe)

Practical Significance

✅ Strategies & Guidance

  • Map Cancer History: Multiple relatives with colon, uterine, ovarian, stomach, or urinary tract cancers (<50 yrs) justify genetic counseling referral.
  • Adhere to Surveillance Intervals: Confirmed carriers follow accelerated gastro/colonoscopy and gynecologic NCCN surveillance schedules.
  • Lifestyle Co-Protection: High dietary fiber, avoiding processed red meats, daily movement, and aspirin chemoprevention (only per specialist guidance) support mucosal health.

⚠️ Clinical Notes & Risks

  • Extra-Colonic Manifestations: MSH2 carriers face elevated uterine/endometrial, ovarian, gastric, and upper urothelial surveillance considerations.
  • Muir-Torre Syndrome Variant: Sebaceous skin neoplasms paired with internal malignancies warrant specialized MMR dermatologic evaluation.
  • False-Negative Consumer Tests: Direct-to-consumer microarrays miss almost all pathogenic MSH2 deletions and frameshifts.
🩺 Medical Disclaimer: Genetic test results for MSH2 (MutS Homolog 2) should always be interpreted alongside laboratory biomarkers, medications, and qualified medical or genetic counseling.

📚 Data Sources

  • OMIM: #609309 (MutS Homolog 2) & #120435 (Lynch Syndrome I)
  • dbSNP & ClinVar: rs2303428, rs4987188, InSiGHT MMR Database
  • NCCN / ESMO Guidelines: Hereditary Colorectal & Endometrial Cancer Management

Last Update: November 2026

Related Research Guides for MSH2

Related Genes in Tumor Suppressor